{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:11:12Z","timestamp":1791839472698,"version":"4.3.4"},"reference-count":127,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genome Ed."],"abstract":"<jats:title>Graphical Abstract<\/jats:title><jats:p\/>","DOI":"10.3389\/fgeed.2022.863651","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T17:35:55Z","timestamp":1652981755000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Development of Therapeutic RNA Manipulation for Muscular Dystrophy"],"prefix":"10.3389","volume":"4","author":[{"family":"Saifullah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Motohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Tsukahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitsugu","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/humu.20918","article-title":"Theoretic Applicability of Antisense-Mediated Exon Skipping for Duchenne Muscular Dystrophy Mutations","volume":"30","author":"Aartsma-Rus","year":"2009","journal-title":"Hum. Mutat."},{"key":"B2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1089\/nat.2018.0756","article-title":"A Sequel to the Eteplirsen Saga: Eteplirsen Is Approved in the United States but Was Not Approved in Europe","volume":"29","author":"Aartsma-Rus","year":"2019","journal-title":"Nucleic Acid Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1021\/bc070060v","article-title":"Pharmacokinetics, Biodistribution, Stability and Toxicity of a Cell-Penetrating Peptide\u2212Morpholino Oligomer Conjugate","volume":"18","author":"Amantana","year":"2007","journal-title":"Bioconjug. Chem."},{"key":"B5","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3233\/jnd-200560","article-title":"Emerging Oligonucleotide Therapeutics for Rare Neuromuscular Diseases","volume":"8","author":"Aoki","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1038\/mt.2010.186","article-title":"In-frame Dystrophin Following Exon 51-Skipping Improves Muscle Pathology and Function in the Exon 52\u2013Deficient <em>mdx<\/em> Mouse","volume":"18","author":"Aoki","year":"2010","journal-title":"Mol. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"13763","DOI":"10.1073\/pnas.1204638109","article-title":"Bodywide Skipping of Exons 45-55 in Dystrophic Mdx52 Mice by Systemic Antisense Delivery","volume":"109","author":"Aoki","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/402369","article-title":"Development of Multiexon Skipping Antisense Oligonucleotide Therapy for Duchenne Muscular Dystrophy","volume":"2013","author":"Aoki","year":"2013","journal-title":"Biomed. Res. Int."},{"key":"B9","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1089\/hum.2006.061","article-title":"Comparative Analysis of Antisense Oligonucleotide Sequences for Targeted Skipping of Exon 51 during Dystrophin Pre-mRNA Splicing in Human Muscle","volume":"18","author":"Arechavala-Gomeza","year":"2007","journal-title":"Hum. Gene Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/gt.2017.90","article-title":"Site-directed RNA Editing by Adenosine Deaminase Acting on RNA for Correction of the Genetic Code in Gene Therapy","volume":"24","author":"Azad","year":"2017","journal-title":"Gene Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2174\/1566523218666181114122116","article-title":"Comparative Activity of Adenosine Deaminase Acting on RNA (ADARs) Isoforms for Correction of Genetic Code in Gene Therapy","volume":"19","author":"Azad","year":"2019","journal-title":"Curr. Gene Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.nmd.2019.10.010","article-title":"The 2020 Version of the Gene Table of Neuromuscular Disorders (Nuclear Genome)","volume":"29","author":"Benarroch","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"B15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1477-7525-10-43","article-title":"Participation and Quality of Life in Children with Duchenne Muscular Dystrophy Using the International Classification of Functioning, Disability, and Health","volume":"10","author":"Bendixen","year":"2012","journal-title":"Health Qual. Life Outcomes"},{"key":"B16","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/protein\/gzz005","article-title":"Genetic Code Restoration by Artificial RNA Editing of Ochre Stop Codon with ADAR1 Deaminase","volume":"31","author":"Bhakta","year":"2019","journal-title":"Protein Eng. Des. Selection"},{"key":"B17","doi-asserted-by":"publisher","first-page":"17304","DOI":"10.1038\/s41598-020-74374-5","article-title":"RNA Editing of BFP, a point Mutant of GFP, Using Artificial APOBEC1 Deaminase to Restore the Genetic Code","volume":"10","author":"Bhakta","year":"2020","journal-title":"Sci. Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"109851","DOI":"10.1016\/j.enzmictec.2021.109851","article-title":"Double MS2 Guided Restoration of Genetic Code in Amber (TAG), Opal (TGA) and Ochre (TAA) Stop Codon","volume":"149","author":"Bhakta","year":"2021","journal-title":"Enzyme Microb. Tech."},{"key":"B19","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/humu.22758","article-title":"The TREAT-NMD DMD Global Database: Analysis of More Than 7,000 Duchenne Muscular Dystrophy Mutations","volume":"36","author":"Bladen","year":"2015","journal-title":"Hum. Mutat."},{"key":"B20","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/embor.2010.208","article-title":"miR\u201031 Modulates Dystrophin Expression: New Implications for Duchenne Muscular Dystrophy Therapy","volume":"12","author":"Cacchiarelli","year":"2011","journal-title":"EMBO Rep."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e2146","DOI":"10.1212\/wnl.0000000000005680","article-title":"Eteplirsen Treatment for Duchenne Muscular Dystrophy","volume":"90","author":"Charleston","year":"2018","journal-title":"Neurology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0140-6736(11)60756-3","article-title":"Exon Skipping and Dystrophin Restoration in Patients with Duchenne Muscular Dystrophy after Systemic Phosphorodiamidate Morpholino Oligomer Treatment: an Open-Label, Phase 2, Dose-Escalation Study","volume":"378","author":"Cirak","year":"2011","journal-title":"The Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, Tolerability, and Efficacy of Viltolarsen in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1126\/science.aaq0180","article-title":"RNA Editing with CRISPR-Cas13","volume":"358","author":"Cox","year":"2017","journal-title":"Science"},{"key":"B25","volume-title":"Dystrophinopathies. GeneReviews\u00ae [Internet]","author":"Darras","year":""},{"key":"B26","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s41580-021-00389-z","article-title":"Molecular and Cellular Basis of Genetically Inherited Skeletal Muscle Disorders","volume":"22","author":"Dowling","year":"2021","journal-title":"Nat. Rev. Mol. Cel Biol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/S0140-6736(74)90071-3","article-title":"PREDNISONE IN DUCHENNE MUSCULAR DYSTROPHY","volume":"304","author":"Drachman","year":"1974","journal-title":"The Lancet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy","volume":"26","author":"Duan","year":"2018","journal-title":"Mol. Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41434-020-0156-6","article-title":"Optimization of Antisense-Mediated Exon Skipping for Duchenne Muscular Dystrophy","volume":"27","author":"Dzierlega","year":"2020","journal-title":"Gene Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1038\/mtna.2014.76","article-title":"Long-Term Efficacy of Systemic Multiexon Skipping Targeting <em>Dystrophin<\/em> Exons 45\u201355 with a Cocktail of Vivo-Morpholinos in <em>Mdx52<\/em> Mice","volume":"4","author":"Echigoya","year":"2015","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1016\/j.ymthe.2017.07.014","article-title":"Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy","volume":"25","author":"Echigoya","year":"","journal-title":"Mol. Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1073\/pnas.1613203114","article-title":"Effects of Systemic Multiexon Skipping with Peptide-Conjugated Morpholinos in the Heart of a Dog Model of Duchenne Muscular Dystrophy","volume":"114","author":"Echigoya","year":"","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/j.ymthe.2019.07.012","article-title":"Exons 45-55 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene","volume":"27","author":"Echigoya","year":"2019","journal-title":"Mol. Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/343180a0","article-title":"Very Mild Muscular Dystrophy Associated with the Deletion of 46% of Dystrophin","volume":"343","author":"England","year":"1990","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1074\/mcp.M113.035600","article-title":"Analysis of the Human Tissue-specific Expression by Genome-wide Integration of Transcriptomics and Antibody-Based Proteomics","volume":"13","author":"Fagerberg","year":"2014","journal-title":"Mol. Cell Proteomics"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1479-0556-4-3","article-title":"Induction of Revertant Fibres in the Mdx Mouse Using Antisense Oligonucleotides","volume":"4","author":"Fall","year":"2006","journal-title":"Genet. Vaccin. Ther"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1038\/s41467-021-22305-x","article-title":"Defective Dystrophic Thymus Determines Degenerative Changes in Skeletal Muscle","volume":"12","author":"Farini","year":"2021","journal-title":"Nat. Commun."},{"key":"B38","volume-title":"FDA grants Accelerated Approval to First Drug for Duchenne Muscular Dystrophy","year":"2016"},{"key":"B39","volume-title":"FDA grants Accelerated Approval to First Targeted Treatment for Rare Duchenne Muscular Dystrophy Mutation","year":"2019"},{"key":"B40","volume-title":"FDA Approves Targeted Treatment for Rare Duchenne Muscular Dystrophy Mutation","year":"2020"},{"key":"B41","volume-title":"FDA Approves Targeted Treatment for Rare Duchenne Muscular Dystrophy Mutation","year":"2021"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1177\/0883073810371129","article-title":"Read-through Strategies for Suppression of Nonsense Mutations in Duchenne\/Becker Muscular Dystrophy: Aminoglycosides and Ataluren (PTC124)","volume":"25","author":"Finkel","year":"2010","journal-title":"J. Child. Neurol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/mt.2010.45","article-title":"Dystrophin Isoform Induction In Vivo by Antisense-Mediated Alternative Splicing","volume":"18","author":"Fletcher","year":"2010","journal-title":"Mol. Ther."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e2270","DOI":"10.1212\/wnl.0000000000009233","article-title":"Increased Dystrophin Production with Golodirsen in Patients with Duchenne Muscular Dystrophy","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1093\/nar\/25.22.4429","article-title":"The Ups and downs of Nucleic Acid Duplex Stability: Structure-Stability Studies on Chemically-Modified DNA:RNA Duplexes","volume":"25","author":"Freier","year":"1997","journal-title":"Nucleic Acids Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2144\/btn-2018-0088","article-title":"Single Nucleotide Recognition Using a Probes-On-Carrier DNA Chip","volume":"66","author":"Fuke","year":"2019","journal-title":"BioTechniques"},{"key":"B47","doi-asserted-by":"publisher","first-page":"41478","DOI":"10.1038\/srep41478","article-title":"Construction of a Guide-RNA for Site-Directed RNA Mutagenesis Utilising Intracellular A-To-I RNA Editing","volume":"7","author":"Fukuda","year":"2017","journal-title":"Sci. Rep."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.stemcr.2018.01.022","article-title":"High-Yield Purification, Preservation, and Serial Transplantation of Human Satellite Cells","volume":"10","author":"Garcia","year":"2018","journal-title":"Stem Cel Rep."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1093\/hmg\/ddu735","article-title":"Toll-like Receptor 4 Ablation in Mdx Mice Reveals Innate Immunity as a Therapeutic Target in Duchenne Muscular Dystrophy","volume":"24","author":"Giordano","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e0161955","DOI":"10.1371\/journal.pone.0161955","article-title":"Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study","volume":"11","author":"Goemans","year":"2016","journal-title":"PLOS ONE"},{"key":"B51","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1146\/annurev-genom-090314-025003","article-title":"The Pathogenesis and Therapy of Muscular Dystrophies","volume":"16","author":"Guiraud","year":"2015","journal-title":"Annu. Rev. Genom. Hum. Genet."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e13243","DOI":"10.15252\/emmm.202013243","article-title":"Delivery of Oligonucleotide\u2010based Therapeutics: Challenges and Opportunities","volume":"13","author":"Hammond","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1080\/15476286.2021.1874161","article-title":"Molecular Correction of Duchenne Muscular Dystrophy by Splice Modulation and Gene Editing","volume":"18","author":"Hanson","year":"2021","journal-title":"RNA Biol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: The Protein Product of the Duchenne Muscular Dystrophy Locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"key":"B55","first-page":"235","article-title":"Phosphorodiamidate Morpholino Oligomers: Favorable Properties for Sequence-specific Gene Inactivation","volume":"3","author":"Iversen","year":"2001","journal-title":"Curr. Opin. Mol. Ther."},{"key":"B56","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1089\/nat.2013.0454","article-title":"A Chemical View of Oligonucleotides for Exon Skipping and Related Drug Applications","volume":"24","author":"J\u00e4rver","year":"2014","journal-title":"Nucleic Acid Ther."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1038\/mt.2008.120","article-title":"Sustained Dystrophin Expression Induced by Peptide-Conjugated Morpholino Oligomers in the Muscles of Mdx Mice","volume":"16","author":"Jearawiriyapaisarn","year":"2008","journal-title":"Mol. Ther."},{"key":"B58","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A Programmable Dual-RNA\u2013Guided DNA Endonuclease in Adaptive Bacterial Immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"B59","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/jhg.2015.115","article-title":"Comparison of Genetic Variation in Drug ADME-Related Genes in Thais with Caucasian, African and Asian HapMap Populations","volume":"61","author":"Jittikoon","year":"2016","journal-title":"J. Hum. Genet."},{"key":"B60","doi-asserted-by":"publisher","first-page":"e0135189","DOI":"10.1371\/journal.pone.0135189","article-title":"DMD Mutations in 576 Dystrophinopathy Families: A Step Forward in Genotype-Phenotype Correlations","volume":"10","author":"Juan-Mateu","year":"2015","journal-title":"PLOS ONE"},{"key":"B61","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41592-019-0323-0","article-title":"In Vivo RNA Editing of point Mutations via RNA-Guided Adenosine Deaminases","volume":"16","author":"Katrekar","year":"2019","journal-title":"Nat. Methods"},{"key":"B62","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/0092-8674(88)90383-2","article-title":"The Complete Sequence of Dystrophin Predicts a Rod-Shaped Cytoskeletal Protein","volume":"53","author":"Koenig","year":"1988","journal-title":"Cell"},{"key":"B63","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.addr.2015.05.008","article-title":"Exon Skipping Therapy for Duchenne Muscular Dystrophy","volume":"87","author":"Kole","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B64","doi-asserted-by":"publisher","first-page":"eaan0713","DOI":"10.1126\/scitranslmed.aan0713","article-title":"Systemic Administration of the Antisense Oligonucleotide NS-065\/NCNP-01 for Skipping of Exon 53 in Patients with Duchenne Muscular Dystrophy","volume":"10","author":"Komaki","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/apa.14568","article-title":"A Mini-Review and Implementation Model for Using Ataluren to Treat Nonsense Mutation Duchenne Muscular Dystrophy","volume":"108","author":"Landfeldt","year":"2019","journal-title":"Acta Paediatr."},{"key":"B66","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.stemcr.2014.10.013","article-title":"Precise Correction of the Dystrophin Gene in Duchenne Muscular Dystrophy Patient Induced Pluripotent Stem Cells by TALEN and CRISPR-Cas9","volume":"4","author":"Li","year":"2015","journal-title":"Stem Cel Rep."},{"key":"B67","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/dddt.s97635","article-title":"Eteplirsen in the Treatment of Duchenne Muscular Dystrophy","volume":"11","author":"Lim","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"B68","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1172\/JCI62656","article-title":"microRNA-206 Promotes Skeletal Muscle Regeneration and Delays Progression of Duchenne Muscular Dystrophy in Mice","volume":"122","author":"Liu","year":"2012","journal-title":"J. Clin. Invest."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1126\/science.1254445","article-title":"Prevention of Muscular Dystrophy in Mice by CRISPR\/Cas9\u2013mediated Editing of Germline DNA","volume":"345","author":"Long","year":"2014","journal-title":"Science"},{"key":"B70","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1177\/1756285610388693","article-title":"Aminoglycoside-induced Mutation Suppression (Stop Codon Readthrough) as a Therapeutic Strategy for Duchenne Muscular Dystrophy","volume":"3","author":"Malik","year":"","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"B71","doi-asserted-by":"publisher","first-page":"NA","DOI":"10.1002\/ana.22024","article-title":"Gentamicin-induced Readthrough of Stop Codons in Duchenne Muscular Dystrophy","volume":"67","author":"Malik","year":"","journal-title":"Ann. Neurol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"Cd003725","DOI":"10.1002\/14651858.CD003725.pub3","article-title":"Glucocorticoid Corticosteroids for Duchenne Muscular Dystrophy","volume":"1","author":"Manzur","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"B73","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/360588a0","article-title":"Association of Dystrophin-Related Protein with Dystrophin-Associated Proteins in Mdx Mouse Muscle","volume":"360","author":"Matsumura","year":"1992","journal-title":"Nature"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in Patients with Nonsense Mutation Duchenne Muscular Dystrophy (ACT DMD): a Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"390","author":"McDonald","year":"2017","journal-title":"Lancet"},{"key":"B75","doi-asserted-by":"publisher","first-page":"630600","DOI":"10.3389\/fgeed.2021.630600","article-title":"Genome Editing in iPSC-Based Neural Systems: From Disease Models to Future Therapeutic Strategies","volume":"3","author":"McTague","year":"2021","journal-title":"Front. Genome Ed."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","article-title":"Dystrophin Immunity in Duchenne's Muscular Dystrophy","volume":"363","author":"Mendell","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the Treatment of Duchenne Muscular Dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann. Neurol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ana.24555","article-title":"Longitudinal Effect of Eteplirsen versus Historical Control on Ambulation in Duchenne Muscular Dystrophy","volume":"79","author":"Mendell","year":"2016","journal-title":"Ann. Neurol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S0140-6736(12)61897-2","article-title":"Muscular Dystrophies","volume":"381","author":"Mercuri","year":"2013","journal-title":"The Lancet"},{"key":"B80","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2217\/cer-2019-0171","article-title":"Safety and Effectiveness of Ataluren: Comparison of Results from the STRIDE Registry and CINRG DMD Natural History Study","volume":"9","author":"Mercuri","year":"2020","journal-title":"J. Comp. Effectiveness Res."},{"key":"B81","doi-asserted-by":"publisher","first-page":"53776","DOI":"10.3791\/53776","article-title":"Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-Linked Muscular Dystrophy","volume":"111","author":"Miskew Nichols","year":"2016","journal-title":"J. Visualized Experiments"},{"key":"B82","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","article-title":"An Explanation for the Phenotypic Differences between Patients Bearing Partial Deletions of the DMD Locus","volume":"2","author":"Monaco","year":"1988","journal-title":"Genomics"},{"key":"B83","doi-asserted-by":"publisher","first-page":"18285","DOI":"10.1073\/pnas.1306243110","article-title":"Correction of Mutations within the Cystic Fibrosis Transmembrane Conductance Regulator by Site-Directed RNA Editing","volume":"110","author":"Montiel-Gonzalez","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B84","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1083\/jcb.111.6.2437","article-title":"Normal Myogenic Cells from Newborn Mice Restore normal Histology to Degenerating Muscles of the Mdx Mouse","volume":"111","author":"Morgan","year":"1990","journal-title":"J. Cel Biol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.3390\/cells8091066","article-title":"Potential Therapies Using Myogenic Stem Cells Combined with Bio-Engineering Approaches for Treatment of Muscular Dystrophies","volume":"8","author":"Motohashi","year":"2019","journal-title":"Cells"},{"key":"B86","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1016\/j.bbamem.2010.02.012","article-title":"Morpholinos and Their Peptide Conjugates: Therapeutic Promise and challenge for Duchenne Muscular Dystrophy","volume":"1798","author":"Moulton","year":"2010","journal-title":"Biochim. Biophys. Acta (Bba) - Biomembranes"},{"key":"B87","doi-asserted-by":"publisher","first-page":"4.30.1","DOI":"10.1002\/cpnc.21","article-title":"Using Morpholinos to Control Gene Expression","volume":"68","author":"Moulton","year":"2017","journal-title":"Curr. Protoc. Nucleic Acid Chem."},{"key":"B88","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.90.15_supplement.S22.001","article-title":"Golodirsen Induces Exon Skipping Leading to Sarcolemmal Dystrophin Expression in Duchenne Muscular Dystrophy Patients with Mutations Amenable to Exon 53 Skipping (S22.001)","volume":"90","author":"Muntoni","year":"2018","journal-title":"Neurology"},{"key":"B89","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/nrd3459","article-title":"Targeting RNA to Treat Neuromuscular Disease","volume":"10","author":"Muntoni","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"B90","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41591-019-0344-3","article-title":"Long-term Evaluation of AAV-CRISPR Genome Editing for Duchenne Muscular Dystrophy","volume":"25","author":"Nelson","year":"2019","journal-title":"Nat. Med."},{"key":"B91","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1006\/mgme.2001.3220","article-title":"Dystrophin and Muscular Dystrophy: Past, Present, and Future","volume":"74","author":"O'Brien","year":"2001","journal-title":"Mol. Genet. Metab."},{"key":"B92","doi-asserted-by":"publisher","first-page":"e2004840117","DOI":"10.1073\/pnas.2004840117","article-title":"Toward the Correction of Muscular Dystrophy by Gene Editing","volume":"118","author":"Olson","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B93","volume-title":"Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau Ministry of Health, Labour and Welfare","year":"2020"},{"key":"B94","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B95","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in Oligonucleotide Drug Delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"B96","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nrd.2017.252","article-title":"Glimmers in Illuminating the Druggable Genome","volume":"17","author":"Rodgers","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"B97","doi-asserted-by":"publisher","first-page":"299rv294","DOI":"10.1126\/scitranslmed.aaa7322","article-title":"Immune-mediated Pathology in Duchenne Muscular Dystrophy","volume":"7","author":"Rosenberg","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"B98","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/nbt.4148","article-title":"Adenine Base Editing in Mouse Embryos and an Adult Mouse Model of Duchenne Muscular Dystrophy","volume":"36","author":"Ryu","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00018-009-0186-0","article-title":"Cell Penetrating Peptides: Overview and Applications to the Delivery of Oligonucleotides","volume":"67","author":"Said Hassane","year":"2010","journal-title":"Cell. Mol. Life Sci."},{"key":"B127","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2144\/btn-2018-0088","article-title":"Single nucleotide recognition using a probes-on-carrier DNA chip","volume":"66","author":"Saifullah","year":"2019","journal-title":"BioTechniques"},{"key":"B100","doi-asserted-by":"publisher","first-page":"8904","DOI":"10.3390\/ijms21238904","article-title":"Effective RNA Knockdown Using CRISPR-Cas13a and Molecular Targeting of the EML4-ALK Transcript in H3122 Lung Cancer Cells","volume":"21","author":"Saifullah","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B101","volume-title":"Proposing a Probes-On-Carrier Based Oligo-DNA Microarray Method for SNPs Detection","author":"Saifullah","year":"2018"},{"key":"B102","doi-asserted-by":"publisher","first-page":"S347","DOI":"10.1016\/j.annonc.2021.05.737","article-title":"P28-11 the CRISPR-Cas13a Gene-Editing System Underlies a Potential Therapeutic Strategy for EML4-ALK-Positive Lung Cancer Cells","volume":"32","author":"Saifullah","year":"2021","journal-title":"Ann. Oncol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"240","DOI":"10.5582\/bst.2018.01102","article-title":"Genotyping of Single Nucleotide Polymorphisms Using the SNP-RFLP Method","volume":"12","author":"Saifullah","year":"2018","journal-title":"Bioscience Trends"},{"key":"B104","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nrd.2016.230","article-title":"A Comprehensive Map of Molecular Drug Targets","volume":"16","author":"Santos","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"B105","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/s41467-020-20123-1","article-title":"Mechanisms of Muscle Atrophy and Hypertrophy: Implications in Health and Disease","volume":"12","author":"Sartori","year":"2021","journal-title":"Nat. Commun."},{"key":"B106","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3390\/jpm10030111","article-title":"Advances in Genetic Characterization and Genotype-Phenotype Correlation of Duchenne and Becker Muscular Dystrophy in the Personalized Medicine Era","volume":"10","author":"Sheikh","year":"2020","journal-title":"J. Personalized Med."},{"key":"B107","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/13543784.2021.1868434","article-title":"Developing DMD Therapeutics: a Review of the Effectiveness of Small Molecules, Stop-Codon Readthrough, Dystrophin Gene Replacement, and Exon-Skipping Therapies","volume":"30","author":"Sheikh","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B108","doi-asserted-by":"publisher","first-page":"E9395","DOI":"10.1073\/pnas.1715320114","article-title":"Site-directed RNA Repair of Endogenous Mecp2 RNA in Neurons","volume":"114","author":"Sinnamon","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B109","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.molmed.2012.09.001","article-title":"Antisense Oligonucleotide Therapeutics for Inherited Neurodegenerative Diseases","volume":"18","author":"Southwell","year":"2012","journal-title":"Trends Mol. Med."},{"key":"B110","doi-asserted-by":"publisher","first-page":"11166","DOI":"10.1002\/anie.201206489","article-title":"An RNA-Deaminase Conjugate Selectively Repairs Point Mutations","volume":"51","author":"Stafforst","year":"2012","journal-title":"Angew. Chem. Int. Ed."},{"key":"B111","doi-asserted-by":"publisher","first-page":"4943","DOI":"10.3390\/ijms21144943","article-title":"Development of a Single Construct System for Site-Directed RNA Editing Using MS2-ADAR","volume":"21","author":"Tohama","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B112","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1089\/nat.2020.0907","article-title":"Immortalized Canine Dystrophic Myoblast Cell Lines for Development of Peptide-Conjugated Splice-Switching Oligonucleotides","volume":"31","author":"Tone","year":"2021","journal-title":"Nucleic Acid Ther."},{"key":"B113","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.ebiom.2019.06.036","article-title":"Peptide-conjugate Antisense Based Splice-Correction for Duchenne Muscular Dystrophy and Other Neuromuscular Diseases","volume":"45","author":"Tsoumpra","year":"2019","journal-title":"EBioMedicine"},{"key":"B114","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1080\/15476286.2017.1387711","article-title":"Abundant Off-Target Edits from Site-Directed RNA Editing Can Be Reduced by Nuclear Localization of the Editing Enzyme","volume":"15","author":"Vallecillo-Viejo","year":"2018","journal-title":"RNA Biol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41582-019-0203-3","article-title":"Therapeutic Developments for Duchenne Muscular Dystrophy","volume":"15","author":"Verhaart","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/path.5263","article-title":"Morpholino\u2010induced Exon Skipping Stimulates Cell\u2010mediated and Humoral Responses to Dystrophin in Mdx Mice","volume":"248","author":"Vila","year":"2019","journal-title":"J. Pathol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/mus.27347","article-title":"Safety, Tolerability, and Pharmacokinetics of Casimersen in Patients with D Uchenne Muscular Dystrophy Amenable to Exon 45 Skipping: A Randomized, Double\u2010blind, Placebo\u2010controlled, Dose\u2010titration Trial","volume":"64","author":"Wagner","year":"2021","journal-title":"Muscle and Nerve"},{"key":"B118","first-page":"93","article-title":"Antisense Treatments for Biothreat Agents","volume":"8","author":"Warfield","year":"2006","journal-title":"Curr. Opin. Mol. Ther."},{"key":"B119","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.omtn.2018.09.017","article-title":"NS-065\/NCNP-01: An Antisense Oligonucleotide for Potential Treatment of Exon 53 Skipping in Duchenne Muscular Dystrophy","volume":"13","author":"Watanabe","year":"2018","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"B120","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nature05756","article-title":"PTC124 Targets Genetic Disorders Caused by Nonsense Mutations","volume":"447","author":"Welch","year":"2007","journal-title":"Nature"},{"key":"B121","doi-asserted-by":"publisher","first-page":"14814","DOI":"10.1073\/pnas.0805676105","article-title":"Effective rescue of Dystrophin Improves Cardiac Function in Dystrophin-Deficient Mice by a Modified Morpholino Oligomer","volume":"105","author":"Wu","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.689533","article-title":"Current Pharmacological Strategies for Duchenne Muscular Dystrophy","volume":"9","author":"Yao","year":"2021","journal-title":"Front. Cel Dev. Biol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1093\/hmg\/ddn293","article-title":"Cell-penetrating Peptide-Conjugated Antisense Oligonucleotides Restore Systemic Muscle and Cardiac Dystrophin Expression and Function","volume":"17","author":"Yin","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"B124","first-page":"179","article-title":"Optimizing Exon Skipping Therapies for DMD","volume":"26","author":"Yokota","year":"2007","journal-title":"Acta Myol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1517\/14712598.2012.693469","article-title":"Exon Skipping for Nonsense Mutations in Duchenne Muscular Dystrophy: Too many Mutations, Too Few Patients?","volume":"12","author":"Yokota","year":"2012","journal-title":"Expert Opin. Biol. Ther."},{"key":"B126","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.ymthe.2004.07.025","article-title":"AAV Vector-Mediated Microdystrophin Expression in a Relatively Small Percentage of Mdx Myofibers Improved the Mdx Phenotype","volume":"10","author":"Yoshimura","year":"2004","journal-title":"Mol. Ther."}],"container-title":["Frontiers in Genome Editing"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgeed.2022.863651\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T15:16:55Z","timestamp":1727277415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgeed.2022.863651\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,10]]},"references-count":127,"alternative-id":["10.3389\/fgeed.2022.863651"],"URL":"https:\/\/doi.org\/10.3389\/fgeed.2022.863651","relation":{},"ISSN":["2673-3439"],"issn-type":[{"value":"2673-3439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,10]]},"article-number":"863651"}}